Actively Recruiting
Phase 12a Study of Durvalumab Combined With Pralatrexate, Romidepsin, and Oral 5-Azacitidine for Treating Relapsed or Refractory Peripheral T-Cell Lymphoma
Led by University of Virginia · Updated on 2022-03-31
148
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying combinations of the drug durvalumab with pralatrexate, romidepsin, and oral 5-azacitidine to treat patients with peripheral T-cell lymphoma PTCL, a rare and aggressive type of non-Hodgkins lymphoma. The study is designed as an open-label Phase 12a trial, with an initial phase 1 dose-finding portion followed by a phase 2 portion for the most promising treatments. The goal is to find the highest safe dose and evaluate safety and effectiveness signals for these drug combinations.
CONDITIONS
Brief Title
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
Research Team
A
Abdelmalek Marian
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here